Scientists are developing all sorts of potential new treatments to tackle the most difficult cancer cases—including some that ...

The combination of RPI, a genetically engineered herpes simplex virus type 1, and Opdivo shrank both injected and non-injected tumors by 30%.

New imaging tools reveal how within an hour of infection, the virus begins to alter our chromosomes to kick-start its own replication.

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global ...

The cold sore-causing Herpes Simplex Virus (HSV-1) hijacks human cells and reconfigures its DNA within just an hour after infection, according to a new study that may help tackle the pathogen. Viruses ...

University of Southern California researchers have found a way to rebrand this oft-embarrassing sore subject by genetically modifying HSV-1 and administering it to patients with treatment-resistant, ...

The herpes simplex virus type 1 (HSV-1), which affects almost two-thirds of the world's population and is generally ...

One-in-six patients treated with the modified virus as part of a clinical trial saw their tumors disappear completely.

Could common viruses silently influence your brain health? Discover what new research reveals about herpes and dementia.

A cancer-killing virus could soon be approved for use after shrinking tumours in a third of people with late-stage melanoma ...

DelveInsight's, “Oncolytic Virus Cancer Therapy Pipeline Insight, 2025,” report provides comprehensive insights about 120+ ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...